An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma

Summary

This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.

Timeline

Start

2025-11-05

Primary completion

2027-04-01

Completion

2027-05-01

Drugs

Indications